La maladie de Parkinson en France (serveur d'exploration)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Occitanie (région administrative)785
O. Rascol130
Occitanie (région administrative) Sauf O. Rascol" 682
O. Rascol Sauf Occitanie (région administrative)" 27
Occitanie (région administrative) Et O. Rascol 103
Occitanie (région administrative) Ou O. Rascol 812
Corpus9014
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 103.
Ident.Authors (with country if any)Title
000278 K. Dujardin [France] ; N. Auzou [France] ; E. Lhommée [France] ; V. Czernecki [France] ; B. Dubois [France] ; A. Fradet [France] ; D. Maltete [France] ; M. Meyer [France] ; F. Pineau [France] ; E. Schmitt [France] ; F. Sellal [France] ; F. Tison [France] ; T. Vidal [France] ; J-P Azulay [France] ; M-L Welter [France] ; J-C Corvol [France] ; F. Durif [France] ; O. Rascol [France]French consensus procedure for assessing cognitive function in Parkinson's disease.
000590 K Ray Chaudhuri [Royaume-Uni] ; A. Rizos [Royaume-Uni] ; C. Trenkwalder [Allemagne] ; O. Rascol [France] ; S. Pal [Royaume-Uni] ; D. Martino [Royaume-Uni] ; C. Carroll [Royaume-Uni] ; D. Paviour [Royaume-Uni] ; C. Falup-Pecurariu [Roumanie] ; B. Kessel [Royaume-Uni] ; M. Silverdale [Royaume-Uni] ; A. Todorova [Royaume-Uni] ; A. Sauerbier [Royaume-Uni] ; P. Odin [Suède] ; A. Antonini [Italie] ; P. Martinez-Martin [Espagne]King's Parkinson's disease pain scale, the first scale for pain in PD: An international validation.
000647 A. Antonini [Italie] ; L. Bauer [Allemagne] ; E. Dohin [France] ; W H Oertel [Allemagne] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; M. Schmid [Allemagne] ; P. Singh [Allemagne] ; E. Tolosa [Espagne] ; K Ray Chaudhuri [Royaume-Uni]Effects of rotigotine transdermal patch in patients with Parkinson's disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial.
000682 P. Odin [Allemagne] ; K. Ray Chaudhuri [Royaume-Uni] ; J T Slevin [États-Unis] ; J. Volkmann [Allemagne] ; E. Dietrichs [Norvège] ; P. Martinez-Martin [Espagne] ; J K Krauss [Allemagne] ; T. Henriksen [Danemark] ; R. Katzenschlager [Autriche] ; A. Antonini [Italie] ; O. Rascol [France] ; Werner Poewe [Autriche]Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program.
000D32 P. Péran [France] ; F. Nemmi ; D. Méligne ; D. Cardebat ; A. Peppe ; O. Rascol ; C. Caltagirone ; J F Demonet ; U. SabatiniEffect of levodopa on both verbal and motor representations of action in Parkinson's disease: a fMRI study.
000D94 Stephan Klebe [France, Allemagne] ; Jean-Louis Golmard [France] ; Michael A. Nalls [États-Unis] ; Mohamad Saad [France] ; Andrew B. Singleton [États-Unis] ; Jose M. Bras [Royaume-Uni] ; John Hardy [Royaume-Uni] ; Javier Simon-Sanchez [États-Unis, Pays-Bas] ; Peter Heutink [Pays-Bas] ; Gregor Kuhlenb Umer [Allemagne] ; Rim Charfi [France, Tunisie] ; Christine Klein [Allemagne] ; Johann Hagenah [Allemagne] ; Thomas Gasser [Allemagne] ; Isabel Wurster [Allemagne] ; Suzanne Lesage [France] ; Delia Lorenz [Allemagne] ; Günther Deuschl [Allemagne] ; Franck Durif [France] ; Pierre Pollak [France] ; Philippe Damier [France] ; François Tison [France] ; Alexandra Durr [France] ; Philippe Amouyel [France] ; Jean-Charles Lambert [France] ; Christophe Tzourio [France] ; Cécilia Maubaret [France] ; Fanny Charbonnier-Beaupel [France] ; Khadija Tahiri [France] ; Marie Vidailhet [France] ; Maria Martinez [France] ; Alexis Brice [France] ; Jean-Christophe Corvol [France] ; Yves Agid [France] ; M. Anheim ; A-M Bonnet ; M. Borg ; A. Brice ; E. Broussolle ; J-C Corvol ; Ph. Damier ; A. Destée ; A. Durr ; F. Durif ; S. Klebe ; E. Lohmann ; M. Martinez ; C. Penet ; P. Pollak ; P. Krack ; O. Rascol ; F. Tison ; C. Tranchant ; M. Vérin ; F. Viallet ; Vincent Plagnol ; Jose M. Bras ; Dena G. Hernandez ; Manu Sharma ; Una-Marie Sheerin ; Mohamad Saad ; Javier Sim N-Sánchez ; Claudia Schulte ; Suzanne Lesage ; Sigurlaug Sveinbjörnsd Ttir ; Philippe Amouyel ; Sampath Arepalli ; Gavin Band ; Roger A. Barker ; Céline Bellinguez ; Yoav Ben-Shlomo ; Henk W. Berendse ; Daniela Berg ; Kailash Bhatia ; Rob Ma De Bie ; Alessandro Biffi ; Bas Bloem ; Zoltan Bochdanovits ; Michael Bonin ; Kathrin Brockmann ; Janet Brooks ; David J. Burn ; Gavin Charlesworth ; Honglei Chen ; Patrick F. Chinnery ; Sean Chong ; Carl E. Clarke ; Mark R. Cookson ; J Mark Cooper ; Jean Christophe Corvol ; Carl Counsell ; Philippe Damier ; Jean-François Dartigues ; Panos Deloukas ; David T. Dexter ; Karin D. Van Dijk ; Allissa Dillman ; Frank Durif ; Sarah Edkins ; Jonathan R. Evans ; Thomas Foltynie ; Colin Freeman ; Jianjun Gao ; Michelle Gardner ; Raphael Gibbs ; Alison Goate ; Emma Gray ; Rita Guerreiro ; Mar Gústafsson ; Clare Harris ; Garrett Hellenthal ; Jacobus J. Van Hilten ; Albert Hofman ; Albert Hollenbeck ; Janice Holton ; Michele Hu ; Xuemei Huang ; Heiko Huber ; Gavin Hudson ; Sarah E. Hunt ; Johanna Huttenlocher ; Thomas Illig ; Pálmi V. J Nsson ; Cordelia Langford ; Andrew Lees ; Peter Lichtner ; Patricia Limousin ; Grisel Lopez ; Delia Lorenz ; Alisdair Mcneill ; Catriona Moorby ; Huw Morris ; Karen E. Morrison ; Ese Mudanohwo ; Sean S. O'Sullivan ; Justin Pearson ; Richard Pearson ; Joel S. Perlmutter ; Hjörvar Pétursson ; Matti Pirinen ; Pierre Pollak ; Bart Post ; Simon Potter ; Bernard Ravina ; Tamas Revesz ; Olaf Riess ; Fernando Rivadeneira ; Patrizia Rizzu ; Mina Ryten ; Stephen Sawcer ; Anthony Schapira ; Hans Scheffer ; Karen Shaw ; Ira Shoulson ; Ellen Sidransky ; Rohan De Silva ; Colin Smith ; Chris Ca Spencer ; Hreinn Stefánsson ; Stacy Steinberg ; Joanna D. Stockton ; Amy Strange ; Zhan Su ; Kevin Talbot ; Carlie M. Tanner ; Avazeh Tashakkori-Ghanbaria ; François Tison ; Daniah Trabzuni ; Bryan J. Traynor ; G. Uitterlinden ; Jana Vandrovcova ; Daan Velseboer ; Marie Vidailhet ; Damjan Vukcevic ; Robert Walker ; Bart Van De Warrenburg ; Michael E. Weale ; Mirdhu Wickremaratchi ; Nigel Williams ; Caroline H. Williams-Gray ; Sophie Winder-Rhodes ; Maria Martinez ; Peter Donnelly ; John Hardy ; Peter Heutink ; Alexis Brice ; Thomas Gasser ; Nicholas W. Wood ; Andrew B. SingletonThe Val158Met COMT polymorphism is a modifier of the age at onset in Parkinson's disease with a sexual dimorphism
000E24 J. J. Ferreira [Portugal] ; R. Katzenschlager [Autriche] ; B. R. Bloem [Pays-Bas] ; U. Bonuccelli [Italie] ; D. Burn [Royaume-Uni] ; G. Deuschl [Allemagne] ; E. Dietrichs [Norvège] ; G. Fabbrini [Italie] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; V. Kostic [Serbie] ; A. Nieuwboer [Belgique] ; P. Odin [Allemagne, Suède] ; Werner Poewe [Autriche] ; O. Rascol [France] ; C. Sampaio [Portugal] ; M. Schüpbach [France, Suisse] ; E. Tolosa [Espagne] ; C. Trenkwalder [Allemagne] ; A. Schapira [Royaume-Uni] ; A. Berardelli [Italie] ; W. H. Oertel [Allemagne]Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease
000E25 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche]Success rate, efficacy, and safety/tolerability of overnight switching from immediate‐ to extended‐release pramipexole in advanced Parkinson's disease
000E44 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; C. Debieuvre [France] ; M. Fraessdorf [Allemagne] ; Werner Poewe [Autriche]Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease
000F76 P. Peran [France, Italie] ; F. Nemmi [Italie] ; D. Meligne [France] ; D. Cardebat [France] ; A. Peppe [Italie] ; O. Rascol [France] ; C. Caltagirone [Italie] ; J. F. Demonet [Suisse] ; U. Sabatini [Italie]Effect of levodopa on both verbal and motor representations of action in Parkinson's disease: A fMRI study
001089 O. Rascol [France] ; J. Bronzova ; R A Hauser ; A E Lang ; C. Sampaio ; A. Theeuwes ; S V Van De WittePardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
001245 S. Perez-Lloret [France, Argentine] ; L. Nègre-Pagès [France] ; A. Ojero-Senard [France] ; P. Damier ; A. Destée ; F. Tison [France] ; M. Merello [Argentine] ; O. Rascol [France]Oro‐buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease: preliminary analysis from the French COPARK cohort
001723 O. Rascol [France]Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged‐release
001838 Werner Poewe [Autriche] ; O. Rascol [France] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno ; M. Haaksma ; L. Salin ; N. Juhel ; A. H. V. SchapiraExtended-release pramipexole in early Parkinson disease: A 33-week randomized controlled trial
001839 A. H. V. Schapira [Royaume-Uni] ; P. Barone [Italie] ; R. A. Hauser [États-Unis] ; Y. Mizuno [Japon] ; O. Rascol [France] ; M. Busse [Allemagne] ; L. Salin [France] ; N. Juhel [France] ; Werner Poewe [Autriche]Extended-release pramipexole in advanced Parkinson disease: A randomized controlled trial
001A08 P. Payoux [France] ; C. Brefel-Courbon ; F. Ory-Magne ; W. Regragui ; C. Thalamas ; S. Balduyck ; F. Durif ; J P Azulay ; F. Tison ; O. Blin ; J P Esquerre ; O. RascolMotor activation in multiple system atrophy and Parkinson disease: a PET study.
001D31 P. Payoux [France] ; C. Brefel-Courbon [France] ; F. Ory-Magne [France] ; W. Regragui [France] ; C. Thalamas [France] ; S. Balduyck [France] ; F. Durif [France] ; J. P. Azulay [France] ; F. Tison [France] ; O. Blin [France] ; J. P. Esquerre [France] ; O. Rascol [France]Motor activation in multiple system atrophy and Parkinson disease: A PET study
002045 A. H. Schapira [Royaume-Uni] ; Yves Agid [France] ; P. Barone [Italie] ; P. Jenner [Royaume-Uni] ; M. R. Lemke [Allemagne] ; Werner Poewe [Autriche] ; O. Rascol [France] ; H. Reichmann [Allemagne] ; E. Tolosa [Espagne]Perspectives on recent advances in the understanding and treatment of Parkinson’s disease
002363 J. C. Sharma [Royaume-Uni] ; I. N. Ross [Royaume-Uni] ; O. Rascol [France] ; D. Brooks [Royaume-Uni]Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight
002443 O. Rascol [France]Thérapeutiques du stade précoce de la maladie de Parkinson
002698 A. Gerdelat-Mas [France] ; M. Simonetta-Moreau [France] ; C. Thalamas [France] ; F. Ory-Magne [France] ; T. Slaoui [France] ; O. Rascol [France] ; C. Brefel-Courbon [France]Levodopa raises objective pain threshold in Parkinson’s disease: a RIII reflex study
002776 T. Slaoui [France] ; A. Mas-Gerdelat [France] ; F. Ory-Magne [France] ; O. Rascol [France] ; C. Brefel-Courbon [France]La lévodopa modifie les seuils nociceptifs chez le patient parkinsonien
002958 J. J. Ferreira [Portugal] ; K. Desboeuf [France] ; M. Galitzky [France] ; C. Thalamas [France] ; C. Brefel-Courbon [France] ; N. Fabre [France] ; J. Senard [France] ; J. Montastruc [France] ; C. Sampaio [Portugal] ; O. Rascol [France]Sleep disruption, daytime somnolence and ‘sleep attacks’ in Parkinson's disease: a clinical survey in PD patients and age‐matched healthy volunteers
002964 M. Horstink [Pays-Bas] ; E. Tolosa [Espagne] ; U. Bonuccelli [Italie] ; G. Deuschl [Allemagne] ; A. Friedman [Pologne] ; P. Kanovsky [République tchèque] ; J. P. Larsen [Norvège] ; A. Lees [Royaume-Uni] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; O. Rascol [France] ; C. Sampaio [Portugal]Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's disease
002D45 Carl E. Clarke [Royaume-Uni] ; O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. Melamed [Israël] ; W. Oertel [Allemagne] ; Werner Poewe [Autriche] ; F. Stocchi [Italie] ; E. Tolosa [Espagne]Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study) : a randomised, double-blind, parallel-group trial. Commentary
002F29 P. Pollak [France] ; F. Tison [France] ; O. Rascol [France] ; A. Destée [France] ; J J Péré [France] ; J M Senard [France] ; F. Durif [France] ; I. Bourdeix [France]Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up
003081 P. Cintas [France] ; M. Simonetta-Moreau ; F. Ory ; C. Brefel-Courbon ; N. Fabre ; P. Chaynes ; J. Sabatier ; J C Sol ; O. Rascol ; I. Berry ; Y. LazorthesDeep brain stimulation for parkinson's disease: correlation between intraoperative subthalamic nucleus neurophysiology and most effective contacts.
003305 O. Rascol [France] ; J J Ferreira ; P. Payoux ; Ch Brefel-Courbon ; J L Montastruc[Management of levodopa-induced dyskinesia].
003311 M. Simonetta Moreau [France] ; S. Meunier ; M. Vidailhet ; S. Pol ; M. Galitzky ; O. RascolTransmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease.
003313 O. Rascol [France] ; P. Payoux ; J. Ferreira ; C. Brefel-CourbonThe management of patients with early Parkinson's disease.
003421 O. Rascol [France] ; J.-J. Ferreira [Portugal] ; P. Payoux [France] ; Ch. Brefel-Courbon [France] ; J.-L. Montastruc [France]Prise en charge des dyskinésies par la lévodopa
003464 M. Simonetta Moreau [France] ; S. Meunier [France] ; M. Vidailhet [France] ; S. Pol [France] ; M. Galitzky [France] ; O. Rascol [France]Transmission of group II heteronymous pathways is enhanced in rigid lower limb of de novo patients with Parkinson's disease
003568 F. Chollet [France] ; I. Loubinoux ; J. Pariente ; C. Carel ; J F Albucher ; O. Rascol ; B. Guiraud-Chaumeil[Pharmacologic modification of cerebral activity: value of functional neuroimaging].
003572 O. Rascol [France] ; N. Fabre ; C. Brefel-Courbon ; J L MontastrucThe pharmacologic treatment of gait ignition failure.
003824 O. Rascol [France] ; J. G. Nutt [États-Unis] ; O. Blin [France] ; C. G. Goetz [États-Unis] ; J. M. Trugman [États-Unis] ; C. Soubrouillard [France] ; J. H. Carter [États-Unis] ; L. J. Currie [États-Unis] ; N. Fabre [France] ; C. Thalamas [France] ; W. J. Giardina [États-Unis] ; S. Wright [États-Unis]Induction by Dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with parkinson Disease
003828 O. Rascol [France] ; I. Arnulf [France] ; H. Peyro-Saint Paul [France] ; C. Brefel-Courbon [France] ; M. Vidailhet [France] ; C. Thalamas [France] ; A. M. Bonnet [France] ; S. Descombes [France] ; B. Bejjani [France] ; N. Fabre [France] ; J. L. Montastruc [France] ; Yves Agid [France]Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease
003839 S. Descombes [France] ; A. M. Bonnet [France] ; U. E. Gasser [Suisse] ; C. Thalamas [France] ; J. Dingemanse [Suisse] ; I. Arnulf [France] ; M. P. Bareille [France] ; Yves Agid [France] ; O. Rascol [France]Dual-release formulation, a novel principle in L-dopa treatment of Parkinson's disease
003864 O. Rascol [France] ; J L Montastruc[Role of dopaminergic agonists].
003869 O. Rascol [France]The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease.
003872 J J Ferreira [France] ; O. RascolPrevention and therapeutic strategies for levodopa-induced dyskinesias in Parkinson's disease.
003895 Jj Ferreira [France, Portugal] ; M. Galitzky [France] ; Jl Montastruc [France] ; O. Rascol [France]Sleep attacks and Parkinson's disease treatment
003B28 O. Rascol [France] ; J.-L. Montastruc [France]La place des agonistes dopaminergiques
003B58 O. Rascol [France]The pharmacological therapeutic management of levodopa-induced dyskinesias in patients with Parkinson's disease
003B73 O. Rascol [France]Medical treatment of levodopa-induced dyskinesias
003C16 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; A. D. Korczyn [Israël] ; P. P. De Deyn [Belgique] ; C. E. Clarke [Royaume-Uni] ; A. E. Lang [Canada]A five-year study of the incidence of dyskinesia in patients with early parkinson's disease who were treated with ropinirole or levodopa
003C55 O. Rascol [France]Dopamine agonists: what is the place of the newer compounds in the treatment of Parkinson's disease?
003C58 O. Rascol [France] ; C. Brefel-Courbon ; S. Descombes ; J L MontastrucClinical pharmacology of levodopa-induced dyskinesia in parkinsonian patients.
003C60 M B Delisle [France] ; J R Murrell ; R. Richardson ; J A Trofatter ; O. Rascol ; X. Soulages ; M. Mohr ; P. Calvas ; B. GhettiA mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy.
003E73 O. Rascol [France]Arguments en faveur du traitement précoce de la maladie de Parkinson par les agonistes dopaminergiques
003F04 C. Thalamas [France] ; A. Taylor [Royaume-Uni] ; C. Brefel-Courbon [France] ; S. Eagle [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; O. Rascol [France]Lack of pharmacokinetic interaction between ropinirole and theophylline in patients with Parkinson's disease
003F05 O. Rascol [France]L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease : A clinical pharmacologic approach
003F34 O. Rascol [France] ; O. Blin [France] ; C. Thalamas [France] ; S. Descombes [France] ; C. Soubrouillard [France] ; P. Azulay [France] ; N. Fabre [France] ; F. Viallet [France] ; K. Lafnitzegger [États-Unis] ; S. Wright [États-Unis] ; J. H. Carter [États-Unis] ; J. G. Nutt [États-Unis]ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's Disease
003F35 H. Bagheri [France] ; C. Damase-Michel [France] ; M. Lapeyre-Mestre [France] ; S. Cismondo [France] ; D. O'Connell [Irlande (pays)] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France]A study of salivary secretion in Parkinson's disease
004109 O. Rascol [France] ; C. Brefel-Courbon [France] ; O. Blin [France]Pharmacologie clinique des dyskinésies induites par la L-dopa chez les malades parkinsoniens
004128 C. Brefel-Courbon [France] ; C. Thalamas [France] ; H. Peyro Saint Paul [France] ; J.-M. Senard [France] ; J.-L. Montastruc [France] ; O. Rascol [France]α2-Adrenoceptor antagonists: A new approach to Parkinson's disease?
004134 A. E. Schrag [Royaume-Uni] ; D. J. Brooks [Royaume-Uni] ; E. Brunt [Pays-Bas] ; D. Fuell [Royaume-Uni] ; A. Korczyn [Israël] ; Werner Poewe [Autriche] ; N. P. Quinn [Royaume-Uni] ; O. Rascol [France] ; F. Stocchi [Italie]The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease
004137 A. D. Korczyn [Israël] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; Werner Poewe [Autriche] ; O. Rascol [France] ; F. Stocchi [Italie]Ropinirole versus bromocriptine in the treatment of early Parkinson's disease : A 6-month interim report of a 3-year study
004138 O. Rascol [France] ; D. J. Brooks [Royaume-Uni] ; E. R. Brunt [Pays-Bas] ; A. D. Korczyn [Israël] ; Werner Poewe [Autriche] ; F. Stocchi [Italie]Ropinirole in the treatment of early Parkinson's disease : A 6-month interim report of a 5-year levodopa-controlled study
004157 J. L. Montastruc [France] ; M. Pelat [France] ; P. Verwaerde [France] ; C. Brefel-Courbon [France] ; M. A. Tran [France] ; O. Blin [France] ; O. Rascol [France] ; J. M. Senard [France]Fluoxetine in orthostatic hypotension of Parkinson's disease : A clinical and experimental pilot study
004161 C. Brefel [France] ; C. Thalamas [France] ; S. Rayet [France] ; A. Lopez-Gil [Royaume-Uni] ; K. Fitzpatrick [Royaume-Uni] ; S. Bullman [Royaume-Uni] ; D. R. Citerone [Royaume-Uni] ; A. C. Taylor [Royaume-Uni] ; J. L. Montastruc [France] ; O. Rascol [France]Effect of food on the pharmacokinetics of ropinirole in parkinsonian patients
004174 D. J. Brooks [Royaume-Uni] ; R. J. Abbott [Royaume-Uni] ; A. J. Lees [Royaume-Uni] ; E. Martignoni [Italie] ; D. V. Philcox [Afrique du Sud] ; O. Rascol [France] ; R. A. C. Roos [Pays-Bas] ; H. J. Sagar [Royaume-Uni]A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease
004365 J.-L. Montastruc [France] ; O. Rascol [France] ; J.-M. Senard [France]Pharmacologie des médicaments antiparkinsoniens : bilan et perspectives : Maladie de Parkinson
004366 N. Fabre [France] ; C. Brefel-Courbon [France] ; O. Rascol [France]Parkinson « plus » : Mouvements anormaux
004387 O. Rascol [France] ; N. Fabre [France] ; U. Sabatini [Italie]Imagerie fonctionnelle
004391 O. Rascol [France] ; N. Fabre [France] ; J.-L. Montastruc [France]Fluctuations de la réponse à la L-dopa dans la maladie de Parkinson : Maladie de Parkinson - 2e partie
004403 C. Soubrouillard [France] ; C. Lombardo [France] ; O. Rascol [France] ; B. Bruguerolle [France] ; O. Blin [France]Agonistes dopaminergiques centraux D1 et traitement de la maladie de Parkinson
004411 O. Rascol [France] ; U. Sabatini [Italie] ; N. Fabre [France] ; C. Brefel [France] ; I. Loubinoux [France] ; P. Celsis [France] ; J. M. Senard [France] ; J. L. Montastruc [France] ; F. Chollet [France]The ipsilateral cerebellar hemisphere is overactive during hand movements in akinetic parkinsonian patients
004420 J. M. Senard [France] ; S. Rai [France] ; M. Lapeyre-Mestre [France] ; C. Brefel [France] ; O. Rascol [France] ; A. Rascol [France] ; J. L. Montastruc [France]Prevalence of orthostatic hypotension in Parkinson's disease
004437 J. L. Montastruc [France] ; O. Rascol [France] ; J. M. Senard [France]Glutamate antagonists and Parkinson's disease : A review of clinical data
004484 J L Montastruc [France] ; J M Senard ; O. Rascol ; A. RascolAutonomic nervous system dysfunction and adrenoceptor regulation in Parkinson's disease. Clinical and pharmacological consequences.
004486 O. Rascol [France] ; A J Lees ; J M Senard ; Z. Pirtosek ; C. Brefel ; J L Montastruc ; D. FuellA placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-DOPA-treated parkinsonian patients.
004661 O. Rascol [France] ; A. J. Lees ; J. M. Senard [France] ; Z. Pirtosek ; J. L. Montastruc [France] ; D. FuellRopinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease
004682 M.-E. Llau [France] ; G. Durrieu [France] ; M.-A. Tran [France] ; J.-M. Senard [France] ; O. Rascol [France] ; J.-L. Montastruc [France]A study of dopaminergic sensitivity in Parkinson's disease : Comparison in ''de novo'' and levodopa-treated patients
004692 J L Montastruc [France] ; O. Rascol ; J M Senard ; G. Houin ; A. RascolSublingual apomorphine: a new pharmacological approach in Parkinson's disease?
004699 J M Sénard [France] ; P. Verwaerde ; O. Rascol ; J L MontastrucEffects of acute levodopa administration on blood pressure and heart variability in never treated parkinsonians.
004900 O. Rascol [France] ; U. Sabatini ; N. Fabre [France] ; J. M. Senard [France] ; M. Simonetta-Moreau [France] ; J. L. Montrastruc [France] ; M. Clanet [France] ; A. Rascol [France]Abnormal vestibuloocular reflex cancellation in multiple system atrophy and progressive supranuclear palsy but not in Parkinson's disease
004912 M E Llau [France] ; L. Nguyen ; J M Senard ; O. Rascol ; J L Montastruc[Drug-induced parkinsonian syndromes: a 10-year experience at a regional center of pharmaco-vigilance].
004942 O. Blin [France] ; C. Desnuelle [France] ; O. Rascol [France] ; M. Borg [France] ; H. Peyro Saint Paul [France] ; J. P. Azulay [France] ; F. Billé [France] ; D. Figarella [France] ; F. Coulom [France] ; J. F. Pellissier [France] ; J. L. Montastruc [France] ; M. Chatel [France] ; G. Serratrice [France]Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy
004A02 O. Rascol [France] ; U. Sabatini [France] ; F. Chollet [France] ; N. Fabre [France] ; J M Senard [France] ; J L Montastruc [France] ; P. Celsis [France] ; J P Marc-Vergnes [France] ; A. Rascol [France]Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa.
004A26 Jl Montastruc [France] ; Me Llau [France] ; O. Rascol [France] ; Jm Senard [France]Drug‐induced parkinsonism: a review
004A44 J L Montastruc [France] ; O. Rascol [France] ; J M Senard [France] ; A. Rascol [France]A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.
004A78 O. Rascol [France] ; N. Fabre [France] ; O. Blin ; J. Poulik [France] ; U. Sabatini [France] ; J.-M. Senard [France] ; M. Ane [France] ; J.-L. Montastruc [France] ; A. RascolNaltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease
004A80 H. Bagheri [France] ; M. Berlan ; J. M. Senard ; O. Rascol ; J. L. MontastrucLacrimation in Parkinson's disease
004A93 J.-F. Demonet [France] ; P. Celsis [France] ; A. Agniel [France] ; D. Cardebat [France] ; O. Rascol [France] ; J.-P. Marc-Vegnes [France]Activation of regional cerebral blood flow by a memorization task in early Parkinson's disease patients and normal subjects
004C26 J. M. Senard [France] ; O. Rascol [France] ; B. Chamontin [France] ; A. Rascol [France] ; J.-L. Montastruc [France]Enregistrement ambulatoire de la pression artérielle dans l'hypotension orthostatique de la maladie de Parkinson
004C51 J. M. Senard [France] ; O. Rascol [France] ; A. Rascol ; J. L. Montastruc [France]Lack of yohimbine effect on ambulatory blood pressure recording : a double-blind cross-over trial in Parkinsonians with orthostatic hypotension
004C61 J. M. Senard [France] ; O. Rascol [France] ; G. Durrieu [France] ; M. A. Tran [France] ; M. Berlan [France] ; A. Rascol ; J. L. MontastrucEffects of Yohimbine on plasma catecholamine levels in orthostatic hypotension related to Pakinson disease or multiple system atrophy
004C65 J. L. Montastruc [France] ; O. Rascol ; J. M. SenardCurrent status of dopamine agonists in Parkinson's disease management
004C70 N. Fabre [France] ; J. L. Montastruc ; O. RascolAlopecia : an adverse effect of bromocriptine
004E33 O. Rascol [France] ; U. Sabatini ; F. Chollet ; P. Celsis ; J.-L. Montastruc ; J.-P. Marc-Vergnes ; A. RascolSupplementary and primary sensory motor area activity in Parkinson's disease : regional cerebral blood flow changes during finger movements and effects of apomorphine
004E38 A. Kastner [France] ; E. C. Hirsch ; O. Lejeune ; F. Javoy-Agid ; O. Rascol [France] ; Yves Agid [France]Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content ?
004F52 A. Agniel [France] ; P. Celsis [France] ; G. Viallard [France] ; J L Montastruc [France] ; O. Rascol [France] ; J F Demonet [France] ; J P Marc-Vergnes [France] ; A. Rascol [France]Cognition and cerebral blood flow in lateralised parkinsonism: lack of functional lateral asymmetries.
004F89 J. L. Montrastuc [France] ; O. Rascol ; J. M. Senard ; V. Gualano ; H. Bagheri ; G. Houin ; A. Lees ; A. RascolSublingual apomorphine in Parkinson's disease : a clinical and pharmacokinetic study
004F90 U. Sabatini [France] ; O. Rascol ; P. Celsis ; G. Houin ; A. Rascol ; J. P. Marc-Vergnes ; J. L. MontastrucSubcutaneous apomorphine increases regional cerebral blood flow in parkinsonian patients via peripheral mechanisms
004F91 O. Rascol [France] ; U. Sabatini ; SIMONETTA-MOREAU ; J. L. Montastruc ; A. Rascol ; M. ClanetSquare wave jerks in Parkinsonian syndromes
005011 G. Durrieu [France] ; J M Senard ; O. Rascol ; M A Tran ; X. Lataste ; A. Rascol ; J L MontastrucBlood pressure and plasma catecholamines in never-treated parkinsonian patients: effect of a selective D1 agonist (CY 208-243).
005036 U. Sabatini [France] ; O. Rascol [France] ; P. Celsis [France] ; J. P. Marc-Vergnes [France] ; J. L. Montastruc [France]Effects of apomorphine on cerebral blood flow and extrapyramidal symptoms in Parkinson's disease
005117 J.-L. Montastruc [France] ; O. Rascol ; J.-M. SenardLes médicaments anti-parkinsoniens : bilan et nouvelles perpectives pharmacologiques
005156 M. Berlan [France] ; O. Rascol ; J. Belin ; J P Moatti ; A. Rascol ; J L MontastrucAlpha 2-adrenergic sensitivity in Parkinson's disease.
005219 J L Montastruc [France] ; O. Rascol [France] ; A. Rascol [France]A randomised controlled study of bromocriptine versus levodopa in previously untreated Parkinsonian patients: a 3 year follow-up.
005926 O. Rascol [France] ; C. Brefel-Courbon ; O. Blin[Clinical pharmacology of dyskinesias induced by L-dopa in Parkinsonian patients].
005945 J L Montastruc [France] ; C. Brefel-Courbon ; J M Senard ; H. Bagheri ; J. Ferreira ; O. Rascol ; M. Lapeyre-MestreSleep attacks and antiparkinsonian drugs: a pilot prospective pharmacoepidemiologic study.
005952 O. Rascol [France] ; D J Brooks ; E. Melamed ; W. Oertel ; Werner Poewe ; F. Stocchi ; E. TolosaRasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

Wicri

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024